SBFM vs. FLGC, BCDA, GOVX, EQ, EDSA, LPTX, MEIP, PRPH, GELS, and ME
Should you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Flora Growth (FLGC), BioCardia (BCDA), GeoVax Labs (GOVX), Equillium (EQ), Edesa Biotech (EDSA), Leap Therapeutics (LPTX), MEI Pharma (MEIP), ProPhase Labs (PRPH), Gelteq (GELS), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry.
Sunshine Biopharma vs.
Sunshine Biopharma (NASDAQ:SBFM) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership.
Sunshine Biopharma has higher earnings, but lower revenue than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Sunshine Biopharma has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500.
Sunshine Biopharma has a net margin of -12.82% compared to Flora Growth's net margin of -30.99%. Sunshine Biopharma's return on equity of -17.89% beat Flora Growth's return on equity.
Sunshine Biopharma presently has a consensus target price of $15.00, suggesting a potential upside of 952.63%. Flora Growth has a consensus target price of $4.00, suggesting a potential upside of 520.16%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Flora Growth.
In the previous week, Flora Growth had 3 more articles in the media than Sunshine Biopharma. MarketBeat recorded 4 mentions for Flora Growth and 1 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 0.57 beat Flora Growth's score of -0.59 indicating that Sunshine Biopharma is being referred to more favorably in the media.
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 0.1% of Sunshine Biopharma shares are owned by insiders. Comparatively, 12.6% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Flora Growth received 13 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 60.00% of users gave Flora Growth an outperform vote.
Summary
Sunshine Biopharma beats Flora Growth on 10 of the 17 factors compared between the two stocks.
Get Sunshine Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sunshine Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:SBFM) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SBFM Stock Free SBFM Stock Alerts